Cilostazol eliminates adverse smoking outcome in patients with drug-eluting stent implantation - Analysis of longer-term follow-up of the CILON-T randomized trial -

Circulation Journal

Volumn 78, Issue 6, 2014, Pages 1420-1427

  Kim, Hack Lyoung ^a   Suh, Jung Won ^d   Lee, Seung Pyo ^a   Kang, Hyun Jae ^a   Koo, Bon Kwon ^a   Cho, Young Seok ^d   Youn, Tae Jin ^d   Chae, In Ho ^d   Choi, Dong Ju ^d   Rha, Seung Woon ^b   Bae, Jang Ho ^e   Kwon, Taek Geun ^e   Bae, Jang Whan ^f   Cho, Myeong Chan ^f   Kim, Hyo Soo ^a,c  

^a Seoul National University Hospital   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Konyang University College of Medicine   (South Korea)

^f Chungbuk National University College of Medicine   (South Korea)

Author keywords

Cilostazol; Percutaneous coronary intervention; Platelet function test; Smoking

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; CLOPIDOGREL; BRONCHODILATING AGENT; TETRAZOLE DERIVATIVE;

ADULT; ARTICLE; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OPEN STUDY; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PREVALENCE; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; THROMBOCYTE FUNCTION; CLINICAL TRIAL; FOLLOW UP; MULTICENTER STUDY;

BRONCHODILATOR AGENTS; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; SMOKING; TETRAZOLES;

EID: 84901335928     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-13-1394     Document Type: Article

References (30)

1. King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A report of the American College of Cardiology/American Heart Association task force on practice guidelines: 2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation 2008; 117: 261-295.
2. Steinhubl SR, Berger PB, Mann JT, Mann JT, Fry ET, Delago A, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 2002; 288: 2411-2420.
3. Dawson DL. Comparative effects of cilostazol and other therapies for intermittent claudication. Am J Cardiol 2001; 87: 19D-27D.
4. Regensteiner JG, Stewart KJ. Established and evolving medical therapies for claudication in patients with peripheral arterial disease. Nat Clin Pract Cardiovasc Med 2006; 3: 604-610.
5. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4(Suppl 2): S14-S19.
6. Shimazawa M, Hara H. Novel situations of endothelial injury in stroke-mechanisms of stroke and strategy of drug development: Protective effects of antiplatelet agents against stroke. J Pharmacol Sci 2011; 116: 30-35.
7. Biondi-Zoccai GG, Lotrionte M, Anselmino M, Moretti C, Testa L, Abbate A, et al. Systematic review and meta-analysis of randomized clinical trials appraising the impact of cilostazol after percutaneous coronary intervention. Am Heart J 2008; 155: 1081-1089.
8. Choi YH, Suh SH, Choi JS, Kim CS, Sim DS, Bae EH, et al. Triple vs. dual antiplatelet therapy in patients with acute myocardial infarction and renal dysfunction. Circ J 2012; 76: 2405-2411.
9. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, et al. Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus: The declare-diabetes trial. J Am Coll Cardiol 2008; 51: 1181-1187.
10. Suh JW, Lee SP, Park KW, Lee HY, Kang HJ, Koo BK, et al. Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Results of the CILON-T trial. J Am Coll Cardiol 2011; 57: 280-289.
11. Brar SS, ten Berg J, Marcucci R, Price MJ, Kim HS, Patti G, et al. Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention: A collaborative meta-analysis of individual participant data. J Am Coll Cardiol 2011; 58: 1945-1954.
12. Sanada S, Nishida M, Ishii K, Moriyama T, Komuro I, Yamauchi-Takihara K. Smoking promotes subclinical atherosclerosis in apparently healthy men: 2-year ultrasonographic follow-up. Circ J 2012; 76: 2884-2891.
13. Rigotti NA, Pasternak RC. Cigarette smoking and coronary heart disease: Risks and management. Cardiol Clin 1996; 14: 51-68.
14. Tonstad S, Andrew Johnston J. Cardiovascular risks associated with smoking: A review for clinicians. Eur J Cardiovasc Prev Rehabil 2006; 13: 507-514.
15. Park KW, Kang SH, Kang J, Jeon KH, Park JJ, Han JK, et al. Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: Additional evidence for the concept of 'smokers' paradox'. Heart 2012; 98: 1000-1006.
16. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, et al. Enhanced clopidogrel responsiveness in smokers: Smokers' paradox is dependent on cytochrome P450 CYP1A2 status. Arterioscler Thromb Vasc Biol 2011; 31: 665-671.
17. Lee SP, Suh JW, Park KW, Lee HY, Kang HJ, Koo BK, et al. Study design and rationale of 'influence of cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drugeluting stent implantation for coronary heart disease. Trials 2010; 11: 87.
18. Malinin A, Pokov A, Spergling M, Defranco A, Schwartz K, Schwartz D, et al. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: The VERIfy Thrombosis risk ASsessment (VERITAS) study. Thromb Res 2007; 119: 277-284.
19. Alexopoulos D, Galati A, Xanthopoulou I, Mavronasiou E, Kassimis G, Theodoropoulos KC, et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: A pharmacodynamic study. J Am Coll Cardiol 2012; 60: 193-199.
20. Ahn CM, Hong SJ, Park JH, Kim JS, Lim DS. Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. Heart Vessels 2011; 26: 502-510.
21. Lee SW, Chun KJ, Park SW, Kim HS, Kim YH, Yun SC, et al. Comparison of triple antiplatelet therapy and dual antiplatelet therapy in patients at high risk of restenosis after drug-eluting stent implantation (from the DECLARE-DIABETES and-Long Trials). J Am Coll Cardiol 2010; 105: 168-173.
22. Friedland SN, Eisenberg MJ, Shimony A. Meta-analysis of randomized controlled trials on effect of cilostazol on restenosis rates and outcomes after percutaneous coronary intervention. Am J Cardiol 2010; 105: 168-173.
23. Singh I, Shafiq N, Pandhi P, Reddy S, Pattanaik S, Sharma Y, et al. Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: An evidence-based approach to answering a clinical query. Br J Clin Pharmacol 2009; 68: 4-13.
24. Tamhane U, Meier P, Chetcuti S, Chen KY, Rha SW, Grossman MP, et al. Efficacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: A meta-analysis of randomised controlled trials. EuroIntervention 2009; 5: 384-393.
25. Zevin S, Benowitz NL. Drug interactions with tobacco smoking: An update. Clin Pharmacokinet 1999; 36: 425-438.
26. Abbas R, Chow CP, Browder NJ, Thacker D, Bramer SL, Fu CJ, et al. In vitro metabolism and interaction of cilostazol with human hepatic cytochrome p450 isoforms. Hum Exp Toxicol 2000; 19: 178-184.
27. Hiratsuka M, Hinai Y, Sasaki T, Konno Y, Imagawa K, Ishikawa M, et al. Characterization of human cytochrome P450 enzymes involved in the metabolism of cilostazol. Drug Metab Dispos 2007; 35: 1730-1732.
28. Kim KS, Park HS, Jung IS, Park JH, Ahn KT, Jin SA, et al. Endothelial dysfunction in the smokers can be improved with oral cilostazol treatment. J Cardiovasc Ultrasound 2011; 19: 21-25.
29. Oida K, Ebata K, Kanehara H, Suzuki J, Miyamori I. Effect of cilostazol on impaired vasodilatory response of the brachial artery to ischemia in smokers. J Atheroscler Thromb 2003; 10: 93-98.
30. Habara S, Mitsudo K, Goto T, Kadota K, Fujii S, Yamamoto H, et al. The impact of lesion length and vessel size on outcomes after sirolimus-eluting stent implantation for in-stent restenosis. Heart 2008; 94: 1162-1165.